<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05112003</url>
  </required_header>
  <id_info>
    <org_study_id>HTC_PTSD_001</org_study_id>
    <nct_id>NCT05112003</nct_id>
  </id_info>
  <brief_title>Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot</brief_title>
  <official_title>Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HealthTech Connex Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre for Neurology Studies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HealthTech Connex Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A growing body of evidence suggests that translingual neurostimulation (TLNS) plays a role in&#xD;
      modulating neuroplastic changes in the brain, which has far-reaching implications for its&#xD;
      ability to facilitate other therapeutic interventions such as cognitive processing therapy&#xD;
      (CPT) for post-traumatic stress disorder (PTSD). The present study aims to assess the&#xD;
      feasibility of combining TLNS with CPT in individuals with PTSD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants screened who are eligible</measure>
    <time_frame>Baseline to week 6</time_frame>
    <description>Reach (RE-AIM framework)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinician-rated symptom severity as measured by CAPS</measure>
    <time_frame>Change from baseline to week 6</time_frame>
    <description>Effectiveness (RE-AIM framework)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant rated symptom severity as measured by the PCL-5</measure>
    <time_frame>Change from baseline to week 6</time_frame>
    <description>Effectiveness (RE-AIM framework)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of therapy visits completed</measure>
    <time_frame>Baseline to Week 6</time_frame>
    <description>Adoption (RE-AIM framework)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ease of protocol administration</measure>
    <time_frame>Baseline to week 6</time_frame>
    <description>Adoption (RE-AIM framework); 5-point Likert scale for participants and therapists</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Qualitative report of barriers and facilitators</measure>
    <time_frame>Baseline to week 6</time_frame>
    <description>Implementation (RE-AIM framework)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electroencephalography (EEG)</measure>
    <time_frame>Change from baseline to week 6</time_frame>
    <description>Using the NeuroCatchTM Platform - EEG amplitudes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroencephalography (EEG)</measure>
    <time_frame>Change from baseline to week 6</time_frame>
    <description>Using the NeuroCatchTM Platform - EEG latencies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generalized Anxiety Disorder 7-item (GAD-7)</measure>
    <time_frame>Change from baseline to week 6</time_frame>
    <description>Anxiety symptom severity self-report measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>Change from baseline to week 6</time_frame>
    <description>Depression symptom severity self-report measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Inventory of Psychosocial Functioning (B-IPF)</measure>
    <time_frame>Change from baseline to week 6</time_frame>
    <description>PTSD-related functional impairment in the prior 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meaning in Life Questionnaire (MLQ)</measure>
    <time_frame>Change from baseline to week 6</time_frame>
    <description>Assesses two dimensions of meaning in life using 10 items rated on a seven-point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from inciting event</measure>
    <time_frame>Baseline</time_frame>
    <description>Time since traumatic event (years)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Post-traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>TLNS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Translingual neurostimulation will be paired with breathing and awareness training prior to CPT sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No TLNS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Translingual neurostimulation</intervention_name>
    <description>The device will be placed into and held in the participant's mouth for 20 minutes while the participant undergoes breathing and awareness training</description>
    <arm_group_label>TLNS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, at least 19 years of age or older&#xD;
&#xD;
          2. A score of 33 or more on the Posttraumatic Stress Disorder Checklist (PCL-5)&#xD;
&#xD;
          3. PTSD symptom duration of ≥ 12 months&#xD;
&#xD;
          4. Stable dose of any medications for the last three months, with no changes anticipated&#xD;
             for the duration of the study&#xD;
&#xD;
          5. Adequate support at home (e.g., family member or caregiver) to ensure assistance in&#xD;
             seeking access to help if needed&#xD;
&#xD;
          6. Able to understand the informed consent form, study procedures and willing to&#xD;
             participate in study&#xD;
&#xD;
          7. Currently has a primary care provider&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of substance dependence or abuse (within the last 3 months)&#xD;
&#xD;
          2. Unstable psychosocial settings (homelessness, lack of support at home)&#xD;
&#xD;
          3. Moderate to high risk of suicidal ideation or behaviour as measured by the Columbia&#xD;
             Suicide Severity Rating Scale (C-SSRS)&#xD;
&#xD;
          4. Current diagnosis of severe anxiety (or score of ≥15 on the GAD-7), severe depression&#xD;
             (or score of ≥20 on the PHQ-9), schizophrenia or bipolar disorder&#xD;
&#xD;
          5. Use of medications for PTSD within the last 6 weeks&#xD;
&#xD;
          6. History of other major neurological disorder (brain cancer, dementia, multiple&#xD;
             sclerosis, stroke)&#xD;
&#xD;
          7. Detection of mild cognitive impairment (mini-ACE score of ≤ 25)&#xD;
&#xD;
          8. Diagnosed epilepsy or history of seizures&#xD;
&#xD;
          9. Not proficient in English&#xD;
&#xD;
         10. Recent (within last 2 years) acquired brain injury&#xD;
&#xD;
         11. Exposed to an investigational drug or device 30 days prior to starting the study, or&#xD;
             concurrent use of an investigational drug or device while enrolled in the study&#xD;
&#xD;
         12. If female and of child-bearing potential: pregnant, suspected or planning to become&#xD;
             pregnant or breast-feeding&#xD;
&#xD;
         13. Contraindicated for the NeuroCatchTM Platform, including:&#xD;
&#xD;
             13.1. Requires the use of hearing aids or a cochlear implant 13.2. Diagnosed with&#xD;
             tinnitus that is currently active 13.3. Has temporary damage to earing (e.g. punctured&#xD;
             ear drum) 13.4. Unable to detect a 740Hz tone played at 85dB in both ears. 13.5.&#xD;
             Implanted pacemaker or implanted electrical stimulators 13.6. Metal or plastic&#xD;
             implants in the skull, excluding dental/facial implants 13.7. Unhealthy scalp&#xD;
             (apparent open wounds and/or bruised or weakened skin) 13.8. Previous exposure to the&#xD;
             NeuroCatch™ Platform audio sequences in the last 3 months&#xD;
&#xD;
         14. Contraindicated for PoNSTM use, including:&#xD;
&#xD;
        14.1. Current disease or sensitivity of the oral cavity 14.2. History of oral cancer 14.3.&#xD;
        Oral surgery within three months of screening 14.4. Oral cavity piercings that could&#xD;
        interfere with PoNSTM use 14.5. Sensitivity to Nickel, Copper, or Gold 14.6. Currently&#xD;
        enrolled in a PoNSTM treatment program or use of the PoNSTM device in the last 5 weeks&#xD;
        14.7. History of penetrating brain injuries 14.8. History of neurodegenerative diseases&#xD;
        14.9. Chronic infectious disease 14.10. Unmanaged hypertension 14.11. Diabetes 14.12.&#xD;
        History of seizures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Natasha Campbell</last_name>
    <phone>778-874-7758</phone>
    <email>natashacampbell@healthtechconnex.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre for Neurology Studies</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Pawlowski</last_name>
      <phone>604-786-0889</phone>
      <email>gabrielapawlowski@healthtechconnex.com</email>
    </contact>
    <investigator>
      <last_name>Venu Karapareddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://centreforneurologystudies.com/neurostimulation-therapy-for-post-traumatic-stress-disorder/</url>
    <description>Study sign-up page</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

